Asgr inhibitors
AssigneeAmgen Inc.
InventorsPaul Nioi, Peter Coward, Christopher Murawsky, Derek E. Piper, Fernando Garces, Jun Zhang, Yang Li, Brian Mingtung Chan
Life of this patent
Estimating the term…
Abstract
Antigen binding proteins that interact with ASGR, ASGR-1 and/or ASGR-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of ASGR, ASGR-1 and/or ASGR-2 antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of interfering RNA compositions that reduce expression of ASGR, ASGR-1 and/or ASGR-2 are described.
Claims22
An isolated antigen binding protein that binds to human ASGR-1 comprising the amino acid sequence of SEQ ID NO:5, wherein the antigen binding protein inhibits ASGR-1 binding to ligand.
-14. (canceled)
An isolated monoclonal antibody, wherein the isolated monoclonal antibody specifically binds to human ASGR-1 and comprises a VH CDR1, VH CDR2 and VH CDR3 having an amino acid sequence identical to or comprising 1, 2, or 3 amino acid residue substitutions in each CDR relative to the antibody VH of any of the sequences set forth in Tables 3-7.
-25. (canceled)
A method of treating or preventing a cardiovascular disease comprising administering to a patient in need thereof a therapeutically effective dose of an inhibitor of ASGR, ASGR-1, and/or ASGR-2.
-38. (canceled)
-43. (canceled)
Dependencies are inferred from the claim text.